



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 30 May 2016 (#16)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- [Answers to Frequently Asked Questions \(FAQs\)](#) about the Fogarty HIV Research Training Program
- Apply to attend the [International Summit in Human Genetics and Genomics](#), sponsored in part by the National Human Genome Research Institute. Selected candidates will be fully sponsored (travel, local transportation, lodging, per diem), for the duration of the Summit. 1-30 September, 2016.
- [Emerging Global Leader Award](#) for LMIC scientists. Application deadline: December 14, 2016
- [Global Brain Disorders Research](#) Application deadline: January 5, 2017
- [Global Noncommunicable Diseases and Injury Research](#) Application deadline: February 22, 2017
- Notice of Change to Key Dates in PAR-16-254 "Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01)" ([NOT-AI-16-054](#))
- Notice to Include Zika Virus Infections in Applications Submitted in Response to RFA-AI-16-001 "Immunity to Neonates and Infants (U01)" ([NOT-AI-16-055](#))
- Change to NIMH Policy for Recruitment of Participants in Clinical Research ([NOT-MH-16-013](#))
- Request for Information (RFI): Guidance for Opportunities in Neuroethics (NIH BRAIN Initiative) ([NOT-MH-16-014](#))
- Request for Information: Soliciting Input for New Research Strategies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) ([NOT-NS-16-024](#))
- Notice of Clarification of Research Areas Included in PAR-16-106 Rapid Assessment of Zika Virus (ZIKV) Complications (R21) ([NOT-NS-16-027](#))
- Request for Information (RFI): Characterizing and Understanding the Organization of Individual Cells within Human Tissues ([NOT-RM-16-025](#))

1. Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [PAR-16-281](#)

Type: D71

Application Due Date: August 25, 2016; August 23, 2017; August 23, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The Fogarty HIV Research Training Program supports research training that strengthens HIV research capacity of institutions in low- and middle-income countries (LMIC). This FOA offers an opportunity for LMIC institutions to submit a planning grant application to participate in the Fogarty HIV Research Training Program. These applications must propose a plan to develop a research training program and the subsequent application that will be submitted in response to the companion D43 FOA ([PAR-16-279](#)). The planned research training program should strengthen research capacity in a defined high priority HIV scientific area ([NOT-OD-15-137](#)) at a specific LMIC institution or at LMIC sites in an established HIV research network.

Budget: Application budgets are limited to \$28,000 direct costs per year exclusive of consortium indirect costs. The maximum project period is 2 years.

2. Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [PAR-16-279](#)

Type: D43

Application Due Date: August 25, 2016; August 23, 2017; August 23, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this FOA is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country. This FOA can support training for a broad range of HIV research areas:

- basic, epidemiologic, clinical, behavioral, and social science research across HIV prevention, care and treatment;
- pathophysiology and therapeutics research to address HIV infection, the effects of HIV on body systems, and HIV's interaction with other co-morbidities and co-infections;
- implementation, operations, health services, and health systems research to improve the HIV prevention, care and treatment care continuum;
- research on HIV co-infections, AIDS-defining and HIV-related cancers, neurological and neuro-psychiatric morbidities, and other co-morbidities and health conditions, both infectious and non-infectious, that contribute to HIV transmission or poor health in HIV-infected individuals, including HIV infected substance (drug and alcohol) users;
- research on integrated bio-behavioral HIV prevention, care and treatment among high risk populations, including polysubstance drug (injection and non-injection) and alcohol use;
- community-based HIV research, HIV research on complex/multi-component interventions, structural interventions, and comparative effectiveness, and HIV research on impact evaluation or health economics;
- cross-disciplinary HIV research among vulnerable or under-researched LMIC populations, including women, substance (drug and alcohol) users, men who have sex with men, transgendered populations, aging populations, orphans, and children;
- clinical research for team members to support HIV clinical research and HIV clinical trials;
- bio-statistics for HIV research design and methodology
- bioinformatics, data analysis, data management, data quality assurance and control to support HIV research;
- laboratory capacity, including bio-safety, and maintenance of lab quality assurance for HIV clinical research.

An application should focus the proposed training program to strengthen research capacity in a defined HIV scientific area at a specific LMIC institution or at LMIC sites in an established HIV research network.

Budget: Application budgets are limited to \$280,000 direct costs per year exclusive of consortium indirect costs. The maximum project period is 5 years.

3. Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [PAR-16-280](#)

Type: G11

Application Due Date: August 25, 2016; August 23, 2017; August 23, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The overall goal of the Fogarty International Center (FIC) HIV Research Training Program is to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research on the evolving HIV epidemic in their countries. This FOA encourages collaborative applications from U.S. and LMIC institutions to support training to achieve technical, administration and financial management expertise required for one of the six research infrastructure functions considered critical to a successful high quality research environment:

- Research administration and management;
- Research integrity oversight;
- Ethical review of research for the protection of human subjects;
- Laboratory animal welfare oversight
- Health sciences library and information services; and
- Information and communications technology systems (ICT) for research

Research infrastructure training programs will maximize previous investments and further strengthen the LMIC institution's research capabilities, and provide more accessible research infrastructure training opportunities to others in their own country and in other LMICs.

Budget: Application budgets are limited to \$92,000 direct costs per year exclusive of consortium indirect costs. The maximum project period is 3 years.

4. Silencing of HIV-1 Proviruses

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [RFA-AI-16-038](#)

Type: R61/R33

Application Due Date: December 7, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages Exploratory and developmental bi-phasic research applications to support the identification and optimization of small molecules or RNAs that interact with host epigenetic machinery to mediate long-term or permanent epigenetic silencing of HIV-1 proviruses.

Budget: Issuing IC and partner components intend to commit an estimated total of \$4.3M to fund 5-7 awards. Application budgets are limited to \$500,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 3 years for the R61 phase and up to 2 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible.

5. Administrative Supplements to Existing NIH Grants and Cooperative Agreements

Letter of Intent due date: N/A

Hyperlink: [\(PA-16-287\)](#)

Type: Admin

Application Due Date: Due dates may vary by awarding IC. See the awarding IC's web site for any applicable application due dates. Apply by 5:00 PM local time of applicant organization. by 5:00 PM local time of applicant organization. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in [Section 8.1.2.11 of the NIH Grants Policy Statement](#)) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. **All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements.** A list of those web sites is available at http://grants.nih.gov/grants/guide/admin_supp/index.htm.

Budget: Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project. The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project, or the cost increases are for unanticipated expenses within the original scope of the project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes. The project and budget periods must be within the currently approved project period for the existing parent award.

6. Factors Underlying Differences in Female and Male Presentation for Dental, Oral, and Craniofacial Diseases and Conditions

Letter of Intent due date: N/A

Hyperlink: [\(PA-16-295\)](#)
[\(PA-16-296\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this funding opportunity announcement (FOA) is to encourage research on mechanisms underlying the manifestations of sex-based differences in Dental, Oral, and Craniofacial (DOC)-related diseases and conditions. Specifically, this initiative encourages studies aimed at understanding immune reactivity, genetic variation, environmental triggers, aging, and hormonal changes as they affect sex-based differences in DOC-related diseases and conditions including, but not limited to, Sjögren's Syndrome (SS), orofacial pain, temporomandibular joint (TMJ) disorder (TMD), salivary gland tumors, and human papillomavirus (HPV)-associated oropharyngeal cancers.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21 - The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

7. Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection

Letter of Intent due date: N/A

Hyperlink: [\(PAR-16-276\)](#)
[\(PAR-16-277\)](#)

Type: R01
R21

Application Due Date: October 13, 2016; June 13, 2017; October 13, 2017; June 13, 2018; October 15, 2018; June 13, 2019 Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. R21 - Direct costs are limited to \$275,000 over an R21 two-year period, with no more than \$200,000 in direct costs allowed in any single year.

8. Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control

Letter of Intent due date: N/A

Hyperlink: [\(PAR-16-278\)](#)

Type: R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Budget: Direct costs are limited to \$275,000 over an R21 two-year period, with no more than \$200,000 in direct costs allowed in any single year.

9. Integrative Research on Polysubstance Abuse and Addiction

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-291\)](#)

Type: R21/R33

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.

Budget: For the R21 phase, the combined budget for direct costs during the two-year project period may not exceed \$275,000 with no more than \$200,000 requested in a single year. For the R33 phase, the direct costs should not exceed \$500,000 per year. The project period is limited to 2 years for the R21 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years.

10. Mobile Health: Technology and Outcomes in Low and Middle Income Countries

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-292\)](#)

Type: R21

Application Due Date: August 31, 2016; August 31, 2017; August 31, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory/developmental research applications that propose to conduct research to develop or adapt innovative mobile health (mHealth) technology specifically suited for low and middle income countries (LMICs) and determine the health-related outcomes associated with implementation of the technology. Of highest interest are innovative, well-designed multidisciplinary projects that aim to generate generalizable knowledge for the field. The overall goal of the FOA is to contribute to the evidence base for the use of mobile technology to improve clinical outcomes and public health while building research capacity in LMICs and establishing research networks in this area. Applicants are required to propose partnerships between at least one U.S. institution and one LMIC institution and the proposed research plan should strengthen the mHealth research capabilities at the LMIC institution.

Budget: Applicants may request up to \$125,000 direct costs per year. The total project period may not exceed 2 years.

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

DP1 – NIH Director’s Pioneer Award (NDPA): To support individuals who have the potential to make extraordinary contributions to medical research. The NIH Director’s Pioneer Award is not renewable.

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P01 – Research Program Projects: For the support of a broadly based, multidisciplinary, often long-term research program which has a specific major objective or a basic theme. A program project generally involves the organized efforts of relatively large groups, members of which are conducting research projects designed to elucidate the various aspects or components of this objective. Each research project is usually under the leadership of an established investigator. The grant can provide support for certain basic resources used by these groups in the program, including clinical components, the sharing of which facilitates the total research effort. A program project is directed toward a range of problems having a central research focus, in contrast to the usually narrower thrust of the traditional research project. Each project supported through this mechanism should contribute or be directly related to the common theme of the total research effort. These scientifically meritorious projects should demonstrate an essential element of unity and interdependence, i.e., a system of research activities and projects directed toward a well-defined research program goal.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R61 – Research Projects Phase 1: As part of a bi-phasic approach to funding exploratory and/or developmental research, the R61 provides support for the first phase of the award. This activity code is used in lieu of the R21 activity code when larger budgets and/or project periods are required to establish feasibility for the project.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

UH2/UH3 – NIH Phase Innovation Awards Cooperative Agreement: To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

U2R – International Research Training Cooperative Agreements: Cooperative agreement mechanism for D43 to support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements (*click on “PA” to search for further funding opportunities*)

RFA Request for Applications (*click on “RFA” to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)

